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Available online at www.sciencedirect.comThe regulation of the immune system is controlled by many cell
surface receptors. A prominent representative is the ‘molecular
switch’ HVEM (herpes virus entry mediator) that can activate
either proinflammatory or inhibitory signaling pathways. HVEM
ligands belong to two distinct families: the TNF-related
cytokines LIGHT and lymphotoxin-a, and the Ig-related
membrane proteins BTLA and CD160. HVEM and its ligands
have been involved in the pathogenesis of various autoimmune
and inflammatory diseases, but recent reports indicate that this
network may also be involved in tumor progression and
resistance to immune response. Here we summarize the recent
advances made regarding the knowledge on HVEM and its
ligands in cancer cells, and their potential roles in tumor
progression and escape to immune responses. Blockade or
enhancement of these pathways may help improving cancer
therapy.
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Introduction
Co-signaling molecules include positive and negative
receptors that allow regulation and fine tuning of the
immune response. They consist of two superfamilies,
classified based on their structure: the tumor necrosis
factor receptor (TNFR) family characterized by
cystein-rich domains (CRDs) in the extracellular portion,
and the immunoglobulin (Ig) superfamily, or ‘CD28 and
B7 family’, whose members contain Ig-variable-like
extracellular domains. The TNFR superfamily comprisesCurrent Opinion in Pharmacology 2012, 12:478–485 important players in costimulation and coinhibition, in-
cluding 4-1BB, OX40, CD27, CD40 and HVEM. Con-
cerning the Ig superfamily, apart from CD28 and ICOS
that deliver co-stimulatory signals to T cells, other mem-
bers of this family are involved in inhibiting or attenuat-
ing TCR-mediated activation. These co-inhibitory Ig
members include CTLA-4, BTLA, PD1, and the recently
discovered molecule CD160.
Here we focus on members of these families that
attracted much attention during these past few years:
the TNF receptor HVEM (herpes virus entry mediator),
a molecular switch between proinflammatory and inhibi-
tory signaling and the HVEM ligands, which are LIGHT
(TNFSF14, lymphotoxin-like, exhibits inducible expres-
sion, and competes with herpes simplex virus (HSV)
glycoprotein D for HVEM, a receptor expressed by T
lymphocytes), BTLA (B and T lymphocyte attenuator)
and CD160. Given the importance of HVEM and its
ligands in the physiopathology of immune regulation, it
is now clear that the dysregulation of this network con-
tributes to various diseases. Many reviews have high-
lighted the interest of manipulating these pathways in
the context of autoimmunity and transplantation [1,2,3].
Recent studies of outstanding interest have also
described abnormal expression of these co-stimulatory
molecules in tumor cells [4,5,6]. Moreover, clinical
trials targeting members of these families, the co-inhibi-
tory Ig molecules CTLA-4 and PD-1 (programmed
death-1), have already given promising results in patients
with melanoma, renal cell and prostate carcinoma, and
non-Hodgkin’s lymphoma [7]. In the same way, there is
clear interest in evaluating the potential role of HVEM
and its ligands in cancer therapy.
In this review we focus on (i) the expression patterns and
function of HVEM and its ligands on normal tissues, (ii)
the expression of these molecules in tumor cells and their
involvement in tumor development and resistance to
cancer, (iii) and the possible exploitation of these path-
ways for novel therapies using antibodies or recombinant
proteins.
Around the HVEM network
TNF-related and unconventional ligands
HVEM, first discovered as the entry route for HSV has the
particularity to connect the two superfamilies. In general,
receptor molecules of the Ig and TNF superfamilies
interact with ligands within the Ig and TNF superfami-
lies, respectively, but not outside of their family. HVEMwww.sciencedirect.com
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Complex binding pattern of HVEM. (a) HVEM has initially been discovered as the coreceptor for the glycoprotein D (gD) of the herpes simplex virus 1
(HSV-1), allowing the entry of the virus in the cell. The TNF-related ligands LIGHT and lymphotoxin-a3, and the Ig-related members BTLA and CD160,
all bind to HVEM. LIGHT also binds LTbR, another TNF receptor member, and the decoy receptor DcR3. CD160 also binds weakly to classical and
non-classical MHC I molecules. The arrows indicate the specific receptor–ligand interaction. The (+) indicates co-stimulatory signaling trough ligation
of LIGHT with HVEM. HVEM signaling with BTLA/CD160 is bidirectional (+/) as BTLA and CD160 transmit inhibitory signals in cells, while BTLA and
CD160 can act as activating ligands for HVEM resulting in NF-kB activation. (b) The diagram illustrates the signaling outcome for HVEM with its ligands
when binding in trans (left) or cis (right) configurations. Both BTLA and CD160 bind the CDR1 domain of HVEM, whereas LIGHT interacts with a region
spanning both the CRD2 and CRD3 domains. In trans configuration, binding of LIGHT to CRD2-CDR3 of HVEM does not inhibit the binding of BTLA or
CD160. By contrast, the HVEM/BTLA cis complex on the same cell interferes with BTLA and CD160 binding in soluble or membrane positions for
accessing and activating HVEM. Only LIGHT in the membrane can drive the dissociation of the HVEM/BTLA cis complex and is capable to activate
HVEM. Soluble LIGHT enhances the binding between HVEM and BTLA but cannot activate HVEM in the cis complex.is different, as it interacts with the viral gD protein and
the TNF-related cytokines: LIGHT and lymphotoxin-a
(LTa) [8]. More surprisingly HVEM was found to inter-
act with two members of the Ig superfamily: BTLA and
CD160 [1,9] (Figure 1A).
Binding sites on HVEM
The extracellular domain of HVEM contains three full
cysteine-rich domains (CRD), the signature motif of the
TNFR superfamily [10]. The fourth C-terminal CRD
has only two of the characteristic three disulfide bonds
that form a CRD. BTLA binds HVEM in CRD1 at the N-
terminus of HVEM [11,12] in a region coined the
‘DARC’ side of HVEM, because it is also the attachment
site for HSV gD (DARC for gD and BTLA binding site
on the TNFR HVEM in CRD1) and CD160 [1]. CRD1 is
essential for inhibitory signaling induced by HVEM as
deletion of this domain abolishes the binding of BTLA
and CD160, but not LIGHT, and results in costimulation
by HVEM-Ig lacking in CRD1 [1]. By contrast, LIGHT
and lymphotoxin-a bind competitively a region spanning
CRD2 and CRD3 on the opposite face of HVEM
[12,13].
The LIGHT/HVEM interaction consists of a trimeric
LIGHT surrounded by an HVEM bound at the interfacewww.sciencedirect.com between each pair of LIGHT monomers thus forming a
3:3 complex typical for TNF family interactions [10].
This leaves the CRD1 of HVEM overhanging the top of
the LIGHT molecule and therefore accessible for inter-
action with CD160 or BTLA. Binding of LIGHT to
HVEM does not block either CD160 or BTLA binding.
Actually, it leads to a twofold increase in CD160 or BTLA
binding. Cross-blocking studies with CD160 and BTLA
indicated that their binding sites on the CRD1 of HVEM
overlapped to some extent. Nevertheless, CD160 and
BTLA do not co-localize on the cell surface [14].
Based on the conservation seen in several TNF ligand–
receptor crystal structures, the engagement of HVEM
with LIGHT must be in trans (between adjacent cells).
By contrast, co-expression of HVEM and BTLA on the
surface of T, B and DCs cells raise the possibility of
some cis interactions on the same cell. This intrinsic
mechanism interferes with the ability of LIGHT in
soluble form, and BTLA and CD160 in soluble or
membrane form to access and activate HVEM
(Figure 1B). Only membrane bound LIGHT is still
capable to activate HVEM, even if activation is less
important than in the absence of BTLA. Thus, BTLA
functions as an inhibitor when coexpressed with
HVEM. The HVEM-BTLA cis complex may provideCurrent Opinion in Pharmacology 2012, 12:478–485
480 Immunomodulationintrinsic regulation in T cells serving as an interference
mechanism silencing signals coming from the micro-
environment [15].
Dual functions of HVEM and its partners
Interestingly, these distinct binding sites on HVEM also
correlate with distinct functions. The binding of HVEM
to LIGHT or LT-a stimulates host immunes responses,
enhancing T cell co-stimulation, B cell costimulation in
cooperation with CD40/CD40L, plasma cell differen-
tiation and Ig secretion [16], and DC maturation [17];
while the binding to BTLA or CD160 delivers co-inhibi-
tory signals to T [6,18,19,20] and B cells [21] (and
ML Thibult et al., 2012, manuscript in preparation). The
discovery of inhibition via HVEM-BTLA provided an
initial explanation to the paradox presented by the dis-
tinct phenotypes of the LIGHT and HVEM-deficient
mice. LIGHT-deficient T cells proliferated poorly in
response to TCR stimulation, as expected; however,
HVEM/ T cells showed enhanced activation [22].
Almost at the same time, BTLA was identified as the first
co-inhibitory receptor of HVEM [11], consistent with
the hyper-responsive phenotype of HVEM-deficient T
cells. Despite the complexity of ligand binding, the
inhibitory function of HVEM is dominant as demon-
strated by HVEM/ mice studies [22] and the inhibi-
tory effect of HVEM-Ig in in vitro studies [14]. CD160
functions are not clearly elucidated as some reports indi-
cated that crosslinking of CD160 resulted in profound
inhibition of human CD4+ T cells [14], whereas cross-
linking of CD160 using BY55 mAb or MHC I multimers
enhanced NK or CD8+ T cell cytolytic activity, as well as
cytokine production (IFN-g, TNFa and IL-6) [23,24].
Therefore, CD160 signaling certainly depends on the cell
type and the extracellular domain engaged. Of note,
HVEM signaling is bidirectional as BTLA and CD160Table 1
Expression of HVEM and its ligands on normal and tumoral cells
Molecule Expression on normal cells 
Positive 
HVEM T cells, B cells, NK cells,
Monocytes, Immature DCs
Primary tumors: CLL, MCL,
Myeloma, Plasma cell leuke
Melanoma (93.75%)
Cell lines: Raji Burkitt lymp
BTLA T cells, B cells, DCs,
Myeloid cells,
Plasmacytoid DC
Primary tumors: CLL, SLL
Microenvironment: TA-spec
CD8+ T cells in melanoma
LIGHT Immature DCs, Monocytes,
Activated T and B cells
CD160 T cells and NK cells CLL, Hairy cell leukemia, M
Abbreviations: CLL: chronic lymphocytic leukemia; MCL: mantle cell lym
leukemia; TA: tumor antigen; DC: dendritic cells; NK: natural killer.
Current Opinion in Pharmacology 2012, 12:478–485 can act as activating ligands for HVEM resulting in NF-
kB activation [25].
Expression patterns in normal cells
Analysis of the HVEM network and the functional out-
come of HVEM engagement with its ligands is compli-
cated by the widespread and regulated expression of
BTLA, CD160, and LIGHT (Table 1).
HVEM is widely expressed on peripheral T and B cells,
and is modulated during the lymphocyte activation:
HVEM is strongly present on resting T cells, downregu-
lated upon T cell activation and then re-expressed as the
T cells return to a more resting state. HVEM expression is
high in naı¨ve and memory B cells, but not detectable on
activated B cells in the germinal centers [16]. Interest-
ingly, expression of HVEM and its ligands is reciprocal, as
HVEM is decreased on DCs, B and T cells following the
engagement with LIGHT [16,17,26] or BTLA [6].
Besides T and B cells, HVEM is expressed on a wide
range of other hematopoietic (monocytes, immature den-
dritic cells, Tregs, monocytes, neutrophils, and NK cells)
and nonhematopoietic cells (parenchymal cells).
By contrast with the wide expression of its receptor
HVEM, LIGHT expression is more restricted and tightly
regulated. LIGHT is induced upon activation of CD4 and
CD8 T cells, and similarly upon activation of B cells with
CD40L/LIGHT signaling [16,27]. As LIGHT levels
increase, HVEM levels coordinately decrease at approxi-
mately the same rate. LIGHT is also expressed on mono-
cytes and is found on immature but not mature DCs.
Indeed, in contrast to LIGHT induction upon T cell
activation, LIGHT is constitutively expressed on ‘imma-
ture’ dendritic cells (DCs), and then down regulated
shortly after maturation induced by LPS stimulation [27].Expression on tumors References
Negative
 ALL,
mia,
homa
Primary tumors: Melanoma (6,25%),
Follicular Lymphoma (26 out of 251
with truncations and frameshift)
Cell lines: DEL Hodgkin’s lymphoma,
Daudi Burkitt lymphoma
[4,6,31,34,
35,36]
ific
Primary tumors: MCL, Marginal zone
lymphoma, Follicular lymphoma, Burkitt
lymphoma, Hodgkin’s lymphoma,
Melanoma
[4,6,18]
Primary tumors: CLL, MCL, ALL,
Myeloma, Plasma cell leukemia,
Hodgkin’s lymphoma, Melanoma
[4,6,31]
CL [5]
phoma; ALL: acute lymphoblastic leukemia; SLL: small lymphocytic
www.sciencedirect.com
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particularly high expression by peripheral B cells and
plasmacytoid dendritic cells (Derre´ et al., unpublished
data) and lower expression by CD11c+ DCs and naive T
cells [28]. Similarly to CTLA-4, ICOS, and PD-1, BTLA
is induced on CD4 T cells during activation. Interest-
ingly, BTLA is expressed on naı¨ve CD8 T cells, and then
progressively downregulated with CD8 differentiation,
which is unusual for inhibitory receptors since most other
inhibitory receptors are absent or low in naı¨ve CD8 T
cells and upregulated with differentiation [6]. More-
over, BTLA remains expressed on Th1 but not Th2 cells,
suggesting that BTLA may specifically downregulate
Th1-mediated inflammatory responses [29].
CD160 expression is highly restricted to circulating NK
cells and T cells. Within subsets of NK cells, CD160 is
expressed on human CD56dimCD16+ NK cells, NKT
cells, and within the subsets of T cells, CD160 is found
on gd T cells, CD8 + CD28- T cells, a small subset of
CD4+ T cells, and all intestinal intraepithelial T cells
(IEL) (CD8 + CD28-CD101+). CD160 is not found on
myeloid or B cells [30].
Expression patterns in cancers
Recently, some groups have reported abnormal expres-
sion of HVEM and its ligands in tumor cells or their
microenvironment (Table 1).
Expression in Chronic lymphocytic leukemia (CLL)
During the past few years, our group focused on expres-
sion and function of HVEM and its ligands on normal and
malignant lymphoid cells. HVEM was expressed on all
normal B-lymphocytes and in most B cell malignancies
[31]: HVEM was systematically expressed in B-chronic
lymphocytic leukemia (B-CLL) and mantle cell lym-
phoma tested, often observed in acute lymphoblastic
leukemia (ALL) and Burkitt’s lymphoma (positive on
Raji but absent on Daudi cell line) and absent in the
Hodgkin’s lymphoma cell line DEL. HVEM was not
expressed in plasma cell lines, whereas it was expressed
in all primary myeloma cells and in plasma cell leukemias.
LIGHT was absent from all the lymphoid cells tested.
In addition to the expression of HVEM, BTLA was
strongly expressed on B-CLL cells by immunohistochem-
istry and flow cytometry, higher as compared with other B-
cell lymphomas [4]. The simultaneous expression of
HVEM and BTLA in CLL cells suggests the triggering
of an ineffective autocrine inhibitory loop. Moreover, we
previously reported high expression of PD-1 on B-CLL
cells [32]. The upregulation of these inhibitory receptors
on CLL precursor cells could be related to the pathogen-
esis of B-CLL, which is considered a monoclonal expan-
sion of antigen-selected B lymphocytes.
Interestingly, although CD160 expression is restricted
to normal NK and T cells and is absent from normal B-www.sciencedirect.com lymphocytes, it is dramatically increased in B cell
malignancies [5,33]. CD160 is expressed in 98%
(590/600) of CLL cases, 100% (32/32) of hairy cell
leukemia, 15% (5/34) of mantle cell lymphoma and
16% (23/45) of other B-malignancies. In another study,
all B-CLL cells also expressed CD160 (53/53) [33].
These co-signaling molecules could contribute to CLL
pathogenesis. CLL cells could use the HVEM, BTLA,
PD-1 inhibitory pathways to inhibit T cells responses and
enhance their survival. Of note, the presence of the
HVEM/BTLA cis complex on the same CLL cell could
prevent the trans ligation of BTLA with HVEM expressed
by T cells, therefore the functional outcome of these co-
expression is complex and the multiple trans and cis inter-
actions have to be considered. The aberrant expression of
BTLA, CD160 and HVEM in CLL makes them potential
cancer biomarkers and attractive targets for immunother-
apy. Moreover, this newly discovered HVEMhi/BTLAhi/
PD1hi/CD160hi phenotype may represent a new property
that can be evaluated by flow cytometry to distinguish B-
CLL from other B cell proliferation disorders.
Triggering on B cell malignancies
On mantle cell lymphoma, engagement of HVEM
increased Fas expression and enhanced the sensitivity
of lymphoma cells to Fas-induced apoptosis [31]. This
suggests that LIGHT stimulation partially reversed the
resistance of lymphoma cells to Fas killing, without
inducing proliferation, which could be an attractive
advantage compared to the CD40/CD40L system. Since
LIGHT triggering also enhances the functions of T-
lymphocytes and dendritic cells, it could be a unique
way to restore an efficient tumor eradication by its pleio-
tropic effects on immune effectors and tumor cells.
In B-CLL cells, engagement of HVEM led to upregula-
tion of chemokine genes such as IL-8 and IP-10, and
apoptosis of leukemic cells, partly depending on the
TRAIL pathway [34]. Interestingly, triggering of
CD160 induced opposite effects on B-CLL cells since
CD160 triggering reduced apoptosis, induced cell cycle
progression and proliferation and cytokine production
(IL-6, IL-8) on B-CLL cells [33].
Expression in lymphoma
By immunohistochemistry in reactive lymph nodes from
benign follicular hyperplasia, BTLA was highly expressed
on naı¨ve B cells of the mantle zone and to a lesser extent on
memory B cells of the marginal zone [4]. By contrast,
within germinal centers B cells were uniformly BTLA-
negative and follicular helper T cells (TFH) were BTLA-
positive. We have previously shown that HVEM was
absent on activated B cells in the germinal center [16].
These findings suggest that downregulation of the HVEM-
BTLA pathway may play a role in germinal center B cell
activation. In malignant lymphomas, we observed thatCurrent Opinion in Pharmacology 2012, 12:478–485
482 ImmunomodulationBTLA was totally absent in follicular lymphoma (0 of 24
positive), mantle cell lymphoma (0 of 10 positive) and
marginal zone lymphoma (0 of 5 positive), which was in
sharp contrast with B-CLL/SLL small lymphocytic leu-
kemia (19 of 19 positive).
HVEM gene mutations in lymphoma
Recently, Cheung and colleagues identified 46 cases
(18.3%) with non-synonymous mutations affecting
TNFRSF14 (the gene coding for HVEM) in a cohort of
251 follicular lymphoma (FL) patients [35]. These
mutations were associated with high-risk clinical features,
and patients with a mutation in TNFRSF14 responded
poorly to rituximab. Of interest, some of these mutations
were located to amino acid residues at positions 14, 23 and
26 (corresponding to exons 1, 1 and 2, respectively), which
were previously described to reduce the binding of
HVEM to BTLA [13].
The effect of these mutations on HVEM/BTLA binding
and function is subject of ongoing investigations. This
opens the possibility of using HVEM as a prognostic
marker for identifying high-risk patients, and adapt thera-
pies accordingly. HVEM appears to be a candidate gene
that might contribute to FL development, given the
frequency of alterations, in particular mutations, in de
novo FL. Another publication by Launay et al. confirmed
TNFRSF14 mutations in FL, with a higher frequency
(44% vs 18% previously), but in their cohort these altera-
tions were not associated with poor prognosis [36].
Further studies are necessary to clarify the impact of
TNFRSF14 mutations on prognosis. These data, together
with the finding that TFH cells are BTLA positive in FL,
suggest that the extinction of HVEM by genetic alterations
in lymphoma might contribute to the maintenance of FL
microarchitecture and pathogenesis.
Expression and function of BTLA and HVEM in
melanoma
Normally, BTLA is downregulated during human CD8+
T cell differentiation to effector cells. However, this is not
the case for tumor-specific T cells as observed in mela-
noma patients. Despite effector differentiation, BTLA
was persistently expressed, associated with limited T cell
expansion and reduced IFN-g production. This suggests
that melanoma-specific CD8 T cell responses are inhib-
ited in vivo via this pathway [6]. Interestingly, vaccina-
tion with peptides and CpG oligodeoxynucleotides
bypassed this BTLA-mediated inhibition, as the
tumor-antigen specific T cells downregulated BTLA.
Importantly, while HVEM was known to be expressed
mainly on lymphoid cells, HVEM was found to be
expressed by melanoma cells in situ and mediated func-
tional inhibition of BTLA+ T cells. Interestingly, 50%
and 25% of metastases from patients were strongly andCurrent Opinion in Pharmacology 2012, 12:478–485 moderately positive for HVEM expression, respectively,
whereas the remaining 25% were weakly positive or
negative. Possibly, HVEM expression may correlate with
disease outcome and/or define subgroups of melanoma. It
was previously observed that HVEM was not expressed in
plasma cell lines, whereas it was expressed in all myeloma
primary cells and in plasma cell leukemias [31]. More-
over, our group showed a high expression of HVEM in a
wide variety of solid tumors (unpublished data). Of note,
HVEM triggering was initially described to inhibit pro-
liferation of adenocarcinoma (HT-29) cells. All together,
these data suggest that HVEM could be involved in the
tumorigenesis and that outside of its costimulatory or
coinhibitory role, HVEM may be considered also on
the ‘tumor suppressor’ side.
Fourcade et al. recently showed that upregulation of BTLA
and PD1 plays a role in restricting NY-ESO-1 specific
CD8+ T cell expansion and function in melanoma
[18]. These studies further support the role of these
inhibitory pathways for immune escape and in impeding
effective anti-tumor T cell immune responses in patients
with advanced melanoma. Blocking experiments showed
that targeting BTLA alone or together with other co-
inhibitory receptors can reverse hyporesponsiveness of
tumor-specific T cells from melanoma patients. Possibly,
simultaneous blockade of BTLA, PD1 and CD160, may
result in an even greater promotion of T cell activation.
Therapeutic perspectives
In the fields of autoimmunity, cell therapy and transplan-
tation, there is great potential for the development of
antibody-based and recombinant protein-based therapies
to interfere with the stimulatory HVEM/LIGHT path-
way and the inhibitory HVEM/BTLA/CD160 pathways.
In autoimmunity and transplantation, one needs to
attenuate undesirable T cell responses against self-anti-
gens and alloantigens, respectively. In the context of anti-
tumor therapy, the goal is to enhance anti-tumor immune
responses. Therapeutic blockade of the CTLA-4 or PD-
1/PD-L1 inhibitory pathways have shown considerable
promise for the treatment of cancer patients, highlighting
the potential clinical benefit of targeting co-receptors [7].
For further development, we can postulate different
approaches summarized in Figure 2:
First, blocking the inhibitory BTLA pathway alone, or
together with PD-1 blockage in tumor-specific lympho-
cytes, using antagonistic mAbs and chemical compounds.
This approach could be pursued in various different can-
cers, as lymphoı¨d malignancies and solid tumors express
HVEM.
Second, therapies targeting the CRD1 of HVEM to block
the binding of BTLA and CD160 represent another
strategy to enhance anti-tumor response.www.sciencedirect.com
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HVEM and its ligands in tumor cells: expression and possible therapeutic manipulations. We present three examples for the role of HVEM and its
ligands in tumor models. ^In melanoma, expression and function of BTLA and PD-1 by tumor antigen-specific CD8+ T cells have been shown,
probably promoting immune escape by HVEM positive tumors. Blocking mAbs against these inhibitory receptors could reverse this inhibitory function.
^B-CLL cells express high levels of HVEM, BTLA, PD-1 and CD160. The co-expression of these co-inhibitory receptors could contribute to CLL
pathogenesis. The presence of the HVEM/BTLA cis complex on the same cell could block the trans interactions with the other ligands of HVEM
expressed on T cells and the functional outcome on T cells responses has to be evaluated. ^Finally, expression of the costimulatory ligand LIGHT in
tumors can promote anti-tumor immunity by inducing chemokine production by stromal cells, and activation of T cells and NK cells.Third, potentiating tumor cell apoptosis, based on the
finding that triggering HVEM can enhance apoptosis of
mantle lymphoma cells and CLL cells mediated by death
receptors.
Finally, triggering of the LIGHT/HVEM costimulatory
pathway, which has been shown to act against cancer in a
murine model. Specifically, LIGHT has the particularity
to stimulate both stroma and T lymphocytes. LIGHT
expression inside tumor cells upregulated chemokines in
stroma probably through interaction with its other re-
ceptor lymphotoxin-b receptor (LTbR) expressed on
stromal cells, forming a microenvironment that attract
naı¨ve T cells. Then, LIGHT costimulation could prime
these T cells at the tumor site, as well as NK cells, leading
to eradication of tumors [37,38].
Conclusions
The co-signaling molecules are crucial for regulating and
maintaining efficient immune responses. Dysfunctions of
the LIGHT-HVEM and BTLA-HVEM pathways are
probably implied in the pathogenesis of various auto-
immune and inflammatory diseases [28]. Dysregulations
of this fine-tuned network are certainly also involved in
neoplastic diseases.www.sciencedirect.com The complexity of the HVEM network and the binding
sites of the different ligands have to be considered for the
development of specific antagonistic or agonistic mAbs,
or recombinant soluble proteins for novel target thera-
pies.
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